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In Parkinson’s disease, the overactivity of
the striatopallidal pathway is thought to
underlie hypokinetic symptoms. In this
study, Cui et al. demonstrate that
astrocytes local to the pallidum play a
crucial role in controlling the gain of
striatopallidal transmission. This
regulatory process goes awry after a
chronic loss of dopamine.
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The prevailing circuit model predicts that hyperac-
tivity of the striatopallidal pathway and subsequently
increased inhibition of external globus pallidus (GPe)
neurons lead to the hypokinetic symptoms of Parkin-
son’s disease (PD). It is believed that hyperactivity
of the striatopallidal pathway is due to inactivity of
dopamine receptors on the somatodendritic mem-
brane of striatopallidal neurons, but the exact cellular
underpinnings remain unclear. In this study, we show
that mouse GPe astrocytes critically control ambient
glutamate level, which in turn gates striatopallidal
transmission via the activation of presynapticmetab-
otropic glutamate receptors. This presynaptic inhibi-
tion of striatopallidal transmission is diminished after
the chronic loss of dopamine. Elevation of intracel-
lular glutamate content in astrocytes restores the
proper regulation of the striatopallidal input in PD
models. These findings argue that astrocytes are
key regulators of the striatopallidal synapse. Target-
ing this cell class may serve as an alternative thera-
peutic strategy for PD.
INTRODUCTION
Astrocytes are integral elements of neural circuits. Through the
expression of a myriad of surface receptors, astrocytes integrate
local and long-range modulatory signals and interact with neu-
rons through the transport and release of neuroactive substrates
(Araque et al., 2014; Halassa et al., 2007; Perea et al., 2009; The-
odosis et al., 2008). As our understanding of the role of astro-
cytes emerged from only a few selected brain areas, we are
just beginning to appreciate the biological importance and dis-
ease relevance of astrocytes in the basal ganglia (Martı´n et al.,
2015; Tong et al., 2014).
Previous studies suggest astrocytes are enriched in the
external globus pallidus (GPe) of the basal ganglia (Lange
et al., 1976; Salvesen et al., 2015). This abundance implies that
astrocytes may play a crucial role in regulating GPe function.
Ultrastructural studies suggest that GPe astrocytic processesCell Repor
This is an open access article undare juxtaposed to striatopallidal terminals and are thus poised
to regulate striatopallidal synaptic transmission (Galvan et al.,
2010). While GPe astrocytes are likely vital in supporting striato-
pallidal transmission via the clearance and recycling of important
substrates, it is unclear whether they actively control striato-
pallidal transmission. Furthermore, we do not know if these
processes are under the influence of dopamine, which is lost in
Parkinson’s disease (PD) (Hornykiewicz, 1998; Wichmann and
DeLong, 1996). Since hyperactive striatopallidal signaling is
thought to underlie hypokinetic symptoms of PD (Kravitz et al.,
2010; Lemos et al., 2016), we sought to determine if disruption
of astrocytic regulation could account for this altered circuit
behavior in PD.
RESULTS
GPe Astrocytes Are Regulated by Dopamine
In keeping with the previous findings of astrocyte enrichment
in the GPe, high levels of GFAP (an astrocytic marker) were
observed in this brain area (Figure 1A; Figure S1). To confirm
the enrichment of astrocytes, neuron and astrocyte abundance
in the GPe was estimated. Accordingly, a GfapCre mouse line
was used to target a broad range of GPe astrocytes. As ex-
pected, Cre-inducible tdTomato expression colocalized with
the astrocyte-specific markers GFAP, Aldh1l1, and S100b (Fig-
ure 1B; Figure S1). Consistent with earlier observations, quanti-
tative analysis of astrocyte (tdTomato+) and neuron (NeuN+)
abundance revealed an enrichment of astrocytes in the GPe.
The astrocyte-to-neuron ratio was an order of magnitude higher
in the GPe than in the dorsal striatum (dStr) (GPe = 1.8 ± 0.4,
dStr = 0.13 ± 0.03; p < 0.0001) (Figure 1B; Table S1). A similar dif-
ference in the astrocyte-to-neuron ratio between the GPe and
the dStr was obtained using S100b as the marker for astrocytes
(GPe = 0.88 ± 0.21, dStr = 0.17 ± 0.04; p < 0.0001).
Astrocytes exhibit spontaneous calcium (Ca2+) transients,
which have important implications in a variety of neural circuits
and provide a useful measure of their physiology (Agulhon
et al., 2008; Bazargani and Attwell, 2016; Khakh and Sofroniew,
2015; Nedergaard et al., 2010; Perea and Araque, 2005; Shige-
tomi et al., 2016). To monitor spontaneous Ca2+ transients in
GPe astrocytes, the expression of a cytosolic Ca2+ sensor was
accomplished with a genetic cross using the same GfapCre
mouse line with a Cre-inducible GCaMP3 mouse line. Similarts 17, 2431–2444, November 22, 2016 ª 2016 The Author(s). 2431
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. The GPe Harbors a High Abundance of Astrocytes that Are Regulated by Dopamine
(A) Confocal micrograph of an adult mouse brain section showing GFAP (green) and NeuN (blue) immunoreactivity in the external globus pallidus (GPe) and the
dorsal striatum (dStr). The two channels are also separated and presented in grayscale. ic, internal capsule.
(B) GfapCre driver line was crossedwith a R26LSL-tdTomato reporter line (GfapCre;R26LSL-tdTomato) to genetically label astrocytes (magenta) in theGPe. The specificity
of Cre-lox-mediated recombination events was demonstrated by the colocalization of tdTomato signal (magenta) with three different astrocyte-specific markers
(green), GFAP, Aldh1l1, and S100b. Boxplots summarized the astrocyte-to-neuron ratios in the dStr and GPe. Density (1,000 cells3mm–3) of genetically labeled
astrocytes (GPe, n = 30 z stacks; dStr, n = 30 z stacks; p < 0.0001) and immunolabeled neuron cell bodies (GPe, n = 30 z stacks; dStr, n = 30 z stacks; p < 0.0001)
were quantified. The astrocyte-neuron ratio was different between the GPe and the dStr (GPe, n = 30 z stacks; dStr, n = 30 z stacks; p < 0.0001). Astrocytic
abundance in the GPe was quantified in two GfapCre;R26LSL-tdTomato mice. Whiskers of the boxplots represent 10–90th percentiles.
(C) A confocal image shows the time-averaged GCaMP3 signals in a GPe astrocyte from a GfapCre;R26LSL-GCaMP3 mouse.
(D) Top: a series of time-lapse images showing compartment-specific dynamics of GCaMP3 signals. Bottom: Ca2+ transientsmeasured in soma and two different
branches are shown.
(E) SR101 was used to define regions of interest (ROIs). A representative spinning-disk confocal image shows SR101-labeled GPe astrocytes.
(F) Representative somatic GCaMP3 signals from GPe astrocytes in different conditions. Five individual GPe astrocytes are shown in each condition.
(G) Stacked bar graph summarizing the percentage of GPe astrocytes that displayed somatic GCaMP3 signals (black or red, active) and those that did not (gray or
pink, silent) in different conditions (naive, n = 413 cells; SKF 81297, n = 109 cells; quinpirole, n = 140 cells; quinpirole and L741626, n = 104 cells; quinpirole and
NGB 2904, n = 123 cells; eticlopride, n = 260 cells; 6-OHDA, n = 91 cells). Dopamine D1 class receptor agonist SKF 81297 did not change the percentage of active
GPe astrocytes compared to the drug-free controls in naive mice (p = 0.7934). Dopamine D2 class receptor agonist quinpirole reduced the percentage of active
astrocytes (p = 0.0011). Co-application of quinpirole and a D2 receptor antagonist L741626 did not block the effect of quinpirole (p = 0.0091). Co-application of
quinpirole with a D3 receptor antagonist NGB 2904 blocked the effect of quinpirole (p = 0.9181). D2 class receptor antagonist eticlopride did not change the
percentage of active GPe astrocytes (p = 0.0946). Chronic 6-OHDA lesion increased the percentage of active astrocytes compared to naive mice (p = 0.0133). All
statistical analyses compared between drug applications or chronic 6-OHDA lesion with drug-free controls in naive mice.to those observed in prototypical astrocytes, GPe astrocytes
displayed somatic Ca2+ transients, spreading waves, and
compartment-specific Ca2+ dynamics (Figures 1C and 1D). So-
matic Ca2+ transients were measured in the subsequent ana-
lyses because of their robustness in detection. Accordingly,
SR101 was used for unbiased identification of the GPe astro-2432 Cell Reports 17, 2431–2444, November 22, 2016cytes’ cell body (Figure 1E) (Nimmerjahn et al., 2004). Sponta-
neous somatic Ca2+ transients were observed in 47.2% of the
astrocyte cell bodies (n = 413 cells) during a 10-min imaging
block (Figures 1F and 1G; Figure S2).
To investigate if GPe astrocytes are under the influence of
dopamine, the effects of bath-applied dopamine receptor
ligands on spontaneous Ca2+ transients were examined. Activa-
tion of D2 class dopamine receptors by quinpirole (10 mM)
reduced the percentage of naive GPe astrocytes that displayed
spontaneous Ca2+ transients when compared to astrocytes in
drug-free imaging fields or slices (see the Supplemental Experi-
mental Procedures) (31.4%, n = 140 cells; p = 0.0011) (Figures 1F
and 1G). This effect was not due to collateral changes in the GPe
neurons’ firing, as quinpirole had no consistent effect on their
firing (Figure S2). Quinpirole-induced suppression of astrocytic
spontaneous Ca2+ transients was blocked with NGB2904
(50 nM), a D3 receptor-specific antagonist (48.0%, n = 123 cells;
p = 0.9181) (Figures 1F and 1G), but not with L741626 (10 nM), a
D2 receptor-specific antagonist (29.8%, n = 104 cells; p =
0.0091) (Figure 1G; Figure S2). Antagonism of D2 class dopa-
mine receptors by eticlopride (100 nM) did not alter the percent-
age of naive GPe astrocytes that displayed spontaneous Ca2+
transients (40.4%, n = 260 cells; p = 0.0946) (Figure 1G; Fig-
ure S2). Similarly, activation of D1 class receptors by SKF
81297 (5 mM) had no effect on the percentage of active GPe as-
trocytes (48.6%, n = 109 cells; p = 0.7934) (Figure 1G; Figure S2).
The duration and amplitude of somatic Ca2+ transients were not
different with pharmacological treatments (Figure S2).
Given astrocyte sensitivity to dopamine receptor modulation,
we next examined if GPe astrocytes are affected by chronic
6-OHDA lesion, which results in extensive dopamine cell loss
in the midbrain, as seen in PD. Spontaneous Ca2+ transients
were observed in a higher percentage of the astrocyte cell
bodies following chronic 6-OHDA lesion when compared to
GPe astrocytes from naive mice (61.5%, n = 91 cells; p =
0.0133). Additionally, increases in both frequency and ampli-
tude of spontaneous Ca2+ transients in GPe astrocytes were
observed under the same experimental conditions (Figures 1F
and 1G; Figure S2). However, these changeswere not the conse-
quence of GPe astrocyte reactivity, as their abundance and
morphological properties were unaltered following chronic
6-OHDA lesion (Figure S1).
An Ambient Glutamate Level Is Maintained in the GPe
Ex Vivo
While our data suggest that GPe astrocytes are under the influ-
ence of dopamine, the exact function of GPe astrocytes remains
to be determined. A prominent feature of GPe astrocytes is their
high expression level of GFAP (Figure 1A; Figure S1). One of the
critical roles of GFAP is the regulation of astrocytic glutamate
transporters (Middeldorp and Hol, 2011). Consistent with this
notion, immunoreactivity for EAAT1 and EAAT2 (also known as
GLAST and GLT1, respectively) was observed throughout the
GPe (Figure S3). We hypothesized that GPe astrocytes are
involved in the maintenance of glutamate homeostasis.
Early kinetic modeling suggests that glutamate transporters
display transport and unbinding of glutamate with equal
probability. In other words, in addition to rapid sequestration of
glutamate, astrocytic glutamate transporters can also maintain
an ambient level of glutamate in the extracellular milieu if
provided with a constant source of glutamate (Tzingounis
and Wadiche, 2007). To examine such a possibility, we investi-
gated the glutamate content in the GPe in ex vivo slices by ex-
pressing a genetically encoded glutamate sensor iGluSnFR(Marvin et al., 2013) on GPe astrocytes. As predicted,
exogenously applied glutamate dose-dependently increased
iGluSnFR signals in ex vivo GPe tissue (Figure 2A). Glutamate
at 10 mM reliably increased iGluSnFR signals by 10%
(1.129 ± 0.052-fold; p < 0.0001). On the other hand, bath
application of NBQX (100 mM, which acts as a non-specific
fluorescence quencher) decreased basal iGluSnFR signals in
ex vivo GPe tissue (0.862 ± 0.021-fold; p < 0.0001). Parallel anal-
ysis in the dStr resulted in a more modest decrease in basal
iGluSnFR signals (0.930 ± 0.030-fold; p < 0.0001) (Figure 2B).
These data argue that a higher level of ambient glutamate was
present in the GPe than in the dStr ex vivo (p = 0.0122). Given
that iGluSnFR displays an affinity for glutamate similar to that
of NMDA receptors (Dingledine et al., 1999; Featherstone and
Shippy, 2008; Marvin et al., 2013; Traynelis et al., 2010), one
should expect tonic NMDA receptor activity in GPe neurons.
Consistent with our hypothesis, whole-cell voltage-clamp re-
cordings from GPe neurons in the presence of tetrodotoxin
(TTX, 1 mM) uncovered that NMDA receptors in ex vivo
GPe tissue were tonically active (Figures 2C–2E).
Ambient Glutamate Gates Striatopallidal GABA
Transmission through Group II mGluR Activation
Previous ultrastructural studies show astrocytic processes are
juxtaposed to the GABAergic striatopallidal terminals (Galvan
et al., 2010). As astrocytic glutamate transporters are present
at GABAergic synapses (Benediktsson et al., 2012; Minelli
et al., 2001), it is plausible that GPe astrocytes control striatopal-
lidal transmission by regulating the ambient glutamate that acts
on presynaptic group II metabotropic glutamate receptors
(mGluRs) (Kalivas, 2009). While mGluR2 (one of the two mem-
bers of group II mGluRs) is not expressed in striatal projection
neurons (SPNs) (Testa et al., 1994), cell-specific expression
analysis showed that mGluR3 is expressed in both direct and in-
direct pathway SPNs (Figure S4). These data are in agreement
with prior observations showing robust mGluR3 in striatal tissue
(Ohishi et al., 1993; Tanabe et al., 1993; Testa et al., 1994).
Therefore, we hypothesize that GPe astrocytes control striato-
pallidal signaling by regulating the availability of glutamate to
mGluR3.
To demonstrate the functional expression of mGluR3 at
the striatopallidal terminals, the effect of group II mGluR activa-
tion on striatopallidal GABA release was examined. Bath appli-
cation of a selective group II mGluR agonist LY379268
(100 nM) reduced (0.5 ± 0.2-fold; p = 0.002) the amplitude
of evoked inhibitory postsynaptic currents (eIPSCs) with a
concomitant increase in their coefficient of variation ([CV] an
indicator of a locus of synaptic modulation) (Del Castillo and
Katz, 1954; Malinow and Tsien, 1990) (control = 0.60 ± 0.13,
LY379268 = 0.96± 0.34; p = 0.0039) (Figures 3A and 3B). Consis-
tent with this observation, LY379268 decreased maximal peak
amplitude (LY379268 = 0.8 ± 0.2-fold; n = 6 cells; p = 0.0313)
and quantal event frequency (control = 22.7 ± 6.0 Hz,
LY379268 = 15.5 ± 5.1 Hz; n = 6 cells; p = 0.0313), but not quantal
IPSC amplitude (control = 60.3 ± 4.2 pA, LY379268 = 64.8 ±
5.3 pA; n = 6 cells; p = 1.0000) in strontium (Sr2+)-containing
external solution, which provided a different metric for estimation
of release (Figure S5). These data are in agreement with ourCell Reports 17, 2431–2444, November 22, 2016 2433
Figure 2. Tonic Activation of iGluSnFR and NMDARecep-
tors in the GPe
(A) Top: a confocal micrograph showing a GPe astrocyte labeled
with SR101. Bottom: dose response of iGluSnFR to exogenously
applied glutamate (100–104 mM) is shown. Means ± SEMs are
presented.
(B) Top: basal iGluSnFR signal (left) in the GPe was attenuated by
the application of NBQX (100 mM, right). Bottom: the correlated
changes in iGluSnFR signal with NBQX in the dStr and the GPe
from single mice are shown. The no-effect line (dotted line) has a
slope = 1. Inset: boxplots show a larger reduction in iGluSnFR
signal in the GPe than in the dStr (GPe, n = 23 slices; dStr, n = 15
slices; p = 0.0122).
(C) Current-voltage relationship of tonic NMDA currents in GPe
neurons, assessed using voltage steps from –120 mV to +70 mV
with 10-mV increments, is shown.
(D) Current-voltage relationship of tonic NMDA currents in GPe
neurons, assessed using a voltage-ramp protocol, is shown.
(E) Left: tonic NMDA currents were revealed by R-CPP (10 mM)
application in GPe neurons that were held at +40 mV. Right:
boxplots summarize the effect of R-CPP on holding currents in
GPe neurons (n = 5 cells, p = 0.0072). A one-sample t test was
used to compare the relative change in holding current after
R-CPP. TTX (1 mM) was included in the perfusate in (C)–(E).
Whiskers of the boxplots represent 10–90th percentiles.hypothesis that group II mGluRs are localized presynaptically on
the striatopallidal terminals.
As we observed that ambient glutamate was present at a con-
centration sufficient to activate iGluSnFR and NMDA receptors
in ex vivoGPe tissue, we examined if ambient glutamate tonically
activates presynaptic group II mGluRs. LY341495 (200 nM, an
antagonist for group II mGluRs) (Schoepp et al., 1999) increased2434 Cell Reports 17, 2431–2444, November 22, 2016(2.3 ± 0.9-fold; p = 0.002) the amplitude of striatopalli-
dal eIPSCs (Figures 3A and 3B). This increase was
accompanied by a reduction in the CV of eIPSCs (con-
trol = 0.60 ± 0.17, LY341495 = 0.26 ± 0.07; p = 0.002)
(Figure 3A). Sequential LY379268 and LY341495 ap-
plications estimated a high level (73.0% ± 19.6%) of
receptor activity in ex vivo slices (Figure 3C). The in-
crease in striatopallidal GABA release with group II
mGluR antagonism was also observed in Sr2+-con-
taining external solution (Figure S5).
The effects produced by LY341495 suggest that a
receptor tone was maintained in the ex vivo slice. To
assert the selective involvement of group II mGluRs,
the effect of MNI-137, a group II mGluR negative allo-
steric modulator (NAM), was examined. MNI-137
(2 mM) produced an increase (2.6 ± 0.8-fold;
p = 0.0313) in striatopallidal eIPSC amplitude with a
reduction in eIPSC CV (control = 0.51 ± 0.18, MNI-
137 = 0.30 ± 0.16; p = 0.0156). The impact of MNI-
137 on eIPSC amplitude was indistinguishable from
that of LY341495 (p = 0.8452) (Figures 3A and 3B).
As a NAM, MNI-137 should, in theory, be inactive in
the absence of the orthosteric ligand (i.e., glutamate).
The effects produced by MNI-137 indicated that the
tonic activity of group II mGluRs at the striatopallidal
synapse was maintained by glutamate in the ex vivoGPe tissue, corroborating the inference drawn from our mea-
surements with iGluSnFR and NMDA receptors.
Lastly, to demonstrate LY341495 did not act directly on GPe
astrocytes, astrocyte spontaneous Ca2+ transients were used
as a readout. LY341495 application did not affect the percentage
of naive GPe astrocytes that displayed spontaneous Ca2+ tran-
sients and does not provide support for the presence of mGluR3
Figure 3. Tonic Group II mGluR Activation
Regulates dStr-GPe GABA Release
(A) Top: representative recordings showing a
suppression of striatopallidal (dStr-GPe) evoked
inhibitory postsynaptic currents (eIPSCs) by
LY379268 (100 nM), a group II mGluR agonist.
Inset: boxplots summarize the effect of LY379268
on eIPSC amplitude (n = 10 cells, p = 0.002) and
CV (n = 10 cells, p = 0.0039). Middle: representa-
tive dStr-GPe eIPSCs show a facilitatory effect by
LY341495 (200 nM), a group II mGluR antagonist.
Inset: boxplots summarize the effect of LY341495
on eIPSC amplitude (n = 10 cells, p = 0.002) and
CV (n = 10 cells, p = 0.002). Bottom: representative
dStr-GPe eIPSCs show a facilitatory effect by
MNI-137 (2 mM), a group II mGluR negative allo-
steric modulator. Inset: boxplots summarize the
effect of MNI-137 on eIPSC amplitude (n = 7 cells,
p = 0.0313) and CV (n = 7 cells, p = 0.0156).
(B) Population time course of LY379268 (top),
LY341495 (middle), and MNI-137 (bottom) on
dStr-GPe eIPSC amplitude is shown.
(C) Left: the basal activity (dotted line) of group II
mGluRs was estimated by maximal receptor
agonism and antagonism using LY379268 and
LY341495, respectively. The population time
course is shown. Right: boxplot summary shows
the resting activity of group II mGluRs on a per-cell
basis (n = 8 cells).
(D) The reliability of the dStr-GPe synapse was
measured with CV–2. LY341495 and MNI-137
caused a similar (p = 0.5362) increase in CV–2
(LY341495, n = 10 cells, p = 0.002; MNI-137, n = 7
cells, p = 0.0156).
Whiskers of the boxplots represent 10–90th per-
centiles. Means ± SEMs are presented for the time
course plots.in GPe astrocytes. In contrast, consistent with the presence of
ambient glutamate in the GPe, the application of MTEP (an
mGluR5 antagonist, 2 mM) decreased the percentage of naive
GPe astrocytes that displayed spontaneous Ca2+ transients
ex vivo (Figure S2).
Neuronal Glutamatergic Inputs Do Not Contribute to
Ambient Glutamate Levels Ex Vivo
As ambient glutamate was present in our ex vivo slice prepara-
tion in the presence of TTX (Figures 2C–2E), this suggests a
possible non-neuronal origin of glutamate. To further investigate
the source of glutamate, the effect of LY341495 on miniature
IPSCs (mIPSCs) of GPe neurons was examined in the presence
of TTX (1 mM) to block action potential-dependent neurotrans-
mitter release. These mIPSCs were considered to originate
largely from striatopallidal synapses (Hegeman et al., 2016;
Shink and Smith, 1995). LY341495 increased the mIPSCCell Reportsfrequency (control = 6.3 ± 1.1 Hz,
LY341495 = 9.7 ± 3.4 Hz; n = 6 cells;
p = 0.0313) without changing the mIPSC
amplitude (control = 46.6 ± 9.9 pA,
LY341495 = 57.6 ± 11.3 pA; n = 6 cells;
p = 0.2188), further suggesting a non-neuronal source of ambient glutamate and a presynaptic locus
of action.
To selectively suppress neuronal glutamatergic input to the
GPe, tetanus toxin light chain (TeTLC)-expressing adeno-asso-
ciated viruses (AAVs) were injected into the subthalamic nucleus
(STN)—the primary neuronal glutamatergic input to the GPe (He-
geman et al., 2016; Jaeger and Kita, 2011) (Figures 4A and 4B).
Alternatively, STN output was silenced using a conditional
VGluT2 knockout (VGluT2-cKO) approach by injecting AAVs
encoding Cre recombinase (Cre-AAV) into the STN of floxed-
VGluT2 mice. To evaluate the effectiveness of the silencing
approaches, their behavioral impact was first examined. Consis-
tent with the circuitry model (Tepper et al., 2007; Albin et al.,
1989; DeLong, 1990), suppression of the STN output greatly
reduced STN-GPe excitatory postsynaptic current (EPSC)
amplitude (control = 135.8 ± 129.4 pA, STN silencing = 12.3 ±
12.3 pA; p = 0.0004) and led to contralateral turning behavior17, 2431–2444, November 22, 2016 2435
Figure 4. Group II mGluRs Are Targeted by a Non-neuronal Source of Glutamate
(A) A confocal micrograph shows the infection of the subthalamic nucleus (STN) with a tetanus toxin light chain and eGFP-expressing adeno-associated virus
(TeTLC-eGFP-AAV). GPi, internal globus pallidus; ic, internal capsule.
(B) Representative recordings showing a near-complete abolishment of STN-GPe excitatory postsynaptic currents (EPSCs) following STN silencing with TeTLC
(bottom) compared to control (top). STN-GPe EPSCs were optogenetically evoked.
(C) Left: summarized boxplots showing that rotational behavior toward the side contralateral to the injection was observed in mice with STN silencing by TeTLC-
eGFP-AAV or VGluT2-cKO. This behavior is different from that produced with STN injection of an eGFP-expressing AAV (control, n = 14 mice; silencing, n = 19
mice; p < 0.0001). Right: boxplots show that STN-GPe EPSC amplitude is largely reduced with STN silencing (n = 19 cells, p = 0.0004).
(D) A representative recording demonstrates the effect of LY341495 (200 nM) on dStr-GPe quantal inhibitory postsynaptic currents (qIPSCs) in mice with STN-
GPe input suppressed with TeTLC-eGFP-AAV infection.
(E) Summarized boxplots show that LY341495 applications consistently produced comparable effects in maximal peak amplitude, frequency, and quantal
amplitude of dStr-GPe qIPSCs (maximal peak: naive, n = 16 cells; TeTLC, n = 8 cells; p = 0.4440; frequency: naive, n = 16 cells; TeTLC, n = 8 cells; p = 0.4440;
quantal amplitude: naive, n = 15 cells; TeTLC, n = 7 cells; p = 0.1481) in mice with STN TeTLC-eGFP-AAV infection compared to naive, non-transduced mice.
(F) A representative recording showing the facilitatory effect of LY341495 on dStr-GPe eIPSCs in VGluT2-cKOmice. Inset: no alteration in the effect of LY341495
is observed in VGluT2-cKO mice compared to naive mice (naive, n = 10 cells; VGluT2-cKO, n = 6 cells; p = 0.9136).
(G) Top: a representative recording showing the lack of an effect of STN conditioning on dStr-GPe eIPSCs. Bottom: a representative recording in a GPe neuron
shows that the STN-conditioning protocol with optogenetic stimulation of STN neurons evoked rapid EPSCs that were temporally synced with the 10-Hz
stimulation pulse (n = 13 cells). Glutamatergic nature of the STN-GPe EPSCwas pharmacologically confirmed with NBQX (5 mM) and R-CPP (20 mM) (n = 3 cells).
Inset: boxplot summary shows that neither eIPSC amplitude (STN stimulation, n = 18 cells, p = 0.5421) nor CV (STN stimulation, n = 18 cells, p = 0.2066) was
affected by STN stimulation.
Whiskers of the boxplots represent 10–90th percentiles.(control = 1.5 ± 2.0 turns, STN silencing = 21.0 ± 5.0 turns;
p < 0.0001) (Figure 4C). Importantly, we did not observe
any alteration in LY341495-induced increase in striatopallidal
eIPSCs when STN output was suppressed either with TeTLC2436 Cell Reports 17, 2431–2444, November 22, 2016(naive = 1.6 ± 0.3-fold, TeTLC = 1.6 ± 0.1-fold; p = 0.4440) or
with VGluT2-cKO (naive = 2.3 ± 0.9-fold, VGluT2-cKO = 2.2 ±
0.1-fold; p = 0.9136) (Figures 4E and 4F). Finally, we tested
whether direct stimulation of the STN input could activate group
Figure 5. Astrocyte-Derived Glutamate
Suppresses dStr-GPe GABA Release via
Group II mGluRs
(A) Using GfapCre driver mouse, astrocyte-specific
ChR2-eYFP expression was rendered with a ge-
netic approach (GfapCre;R26LSL-ChR2(H314R)-eYFP).
Left: confocal micrographs show ChR2-eYFP
signal in a sagittal mouse brain section. Right:
high-magnification image shows intense ChR2-
eYFP signal in the GPe neuropil. dStr, dorsal
striatum; ic, internal capsule.
(B) Optogenetic activation of astrocytes induced
slow inward currents recorded inGPe neurons (n =
12 cells). These currents were sensitive to NMDA
and AMPA receptor antagonists, R-CPP (20 mM)
and NBQX (5 mM) (n = 7 cells).
(C) Left: representative dStr-GPe qIPSCs re-
corded in GPe neurons before (control) and
during optogenetic astrocyte activation. Note
the decrease in both maximal peak amplitude (n =
12 cells, p = 0.0005) and event frequency (n = 12
cells, p = 0.0005). LY341495 (200 nM) pre-
incubation completely abolished this effect
(maximal peak: n = 10 cells, p = 0.1934; frequency:
n = 10 cells, p = 0.1602). The effect of astrocyte
activation on dStr-GPe qIPSCs was reduced by
LY341495 (maximal peak amplitude: p = 0.0004;
frequency: p = 0.0033). This is summarized in
a boxplot format (right).
(D) Left: representative dStr-GPe eIPSCs showing
the effect of optogenetic astrocyte activation on
dStr-GPe GABA release. Right: a population time
course illustrates the stability of the recording and
the consistency of the effect across cells. This
effect was reversed by LY341495 (200 nM). Inset:
boxplots summarize the effect of optogenetic
astrocyte activation on dStr-GPe eIPSC amplitude
(n = 8 cells, p = 0.0078) and CV (n = 8 cells,
p = 0.0234).
(E) MSO (5 mM), a glutamine synthetase inhibitor,
was bath applied to elevate intracellular glutamate
content within astrocytes. Left: representative
dStr-GPe eIPSCs show the effect of MSO on
dStr-GPe GABA release. Right: a population time
course illustrates the stability of the recording and
the consistency of the effect across cells. This
effect was reversed by LY341495 (200 nM). Inset:
boxplots summarize the effect of MSO on dStr-
GPe eIPSC amplitude (n = 8 cells, p = 0.0078)
and CV (n = 8 cells, p = 0.0078).
Whiskers of the boxplots represent 10–90th per-
centiles. Means ±SEMs are presented for the time
course plots.II mGluRs. Optogenetic activation of the STN input reliably
evoked ionotropic GluR-mediated EPSCs in all GPe neurons
examined (n = 13 cells) (Figure 4G; Figure S3). In contrast, the
same stimulation paradigm did not have a consistent effect on
striatopallidal eIPSC amplitude (1.1 ± 0.5-fold, p = 0.5421)
(Figure 4G).
Astrocyte-DerivedGlutamate ActivatesGroup IImGluRs
at the Striatopallidal Terminals
Our data suggest a non-neuronal origin of ambient glutamate
in ex vivo GPe tissue. In fact, the capacity for astrocytesto release glutamate is well described (Araque et al., 2014;
Hamilton and Attwell, 2010; Haydon, 2001; Malarkey and Par-
pura, 2008; Newman, 2003; Theodosis et al., 2008; Volterra
and Meldolesi, 2005). To directly demonstrate the capacity
for GPe astrocytes to release glutamate, we expressed chan-
nelrhodopsin-2 (ChR2) in astrocytes (Gourine et al., 2010; Perea
et al., 2014; Sasaki et al., 2012) using a GfapCre transgenic
line (Figure 5A). Consistent with Cre-inducible tdTomato and
GCaMP3 expression patterns (Figure 1), Cre-inducible ChR2
expression in the GPe was restricted to astrocytes (Figure S3).
Optogenetic activation of GPe astrocytes excited neighboringCell Reports 17, 2431–2444, November 22, 2016 2437
neurons, as evidenced by the increased firing and the corre-
sponding slow inward currents (Figure 5B; Figure S3). These ef-
fects were sensitive to ionotropic glutamate receptor blockers
NBQX (5 mM) and R-CPP (20 mM) (Figure 5B), but they were
insensitive to TTX, SR95531, and picrotoxin (data not shown).
These results confirmed that GPe astrocytes can indeed release
glutamate.
We next examined if optogenetically evoked, astrocytic gluta-
mate release could impact striatopallidal GABA transmission.
To avoid confounding effects associated with the release of en-
docannabinoids (Navarrete and Araque, 2010), AM251 (a CB1
receptor antagonist, 2 mM) was included throughout the experi-
ments. Under this condition, optogenetic activation of astrocytes
reduced striatopallidal eIPSC amplitude (astrocyte activation =
0.7 ± 0.1-fold; p = 0.0078), accompanied by an increase in CV
(control = 0.53 ± 0.13, astrocyte activation = 0.72 ± 0.22; p =
0.0234) (Figure 5D). Similarly, a decrease in striatopallidal
quantal GABA release was observed in Sr2+-containing external
solution (Figure 5C). Group II mGluRs were crucial in mediating
these effects, as preincubation of ex vivo slices in LY341495
completely blocked the ability of astrocyte activation to sup-
press GABA release (maximal peak = 0.9 ± 0.1-fold, p =
0.1934; frequency = 1.0 ± 0.1-fold, p = 0.1602) (Figure 5C). In
contrast, the effect of optogenetic activation of astrocytes on
striatopallidal eIPSC amplitude was not altered by the applica-
tion of PSB36 (an adenosine A1 receptor antagonist, 10 nM)
(naive = 0.7 ± 0.1-fold, n = 8 cells; PSB36 = 0.6 ± 0.2-fold,
n = 7 cells; p = 0.7505). These findings corroborate those from
experiments where no exogenous stimulus was applied, demon-
strating that glutamate suppresses striatopallidal GABA release
via the activation of group II mGluRs.
Given these results, inhibiting glutamine synthetase with
methionine sulfoximine (MSO), which promotes astrocytic
glutamate release by elevating cytosolic glutamate content
(Tani et al., 2014), should inhibit striatopallidal GABA release.
Consistent with our hypothesis, bath application of MSO
(5 mM) decreased the striatopallidal eIPSC amplitude (MSO =
0.4 ± 0.2-fold; p = 0.0078) and increased the CV (control =
0.52 ± 0.15, MSO = 1.10 ± 0.33; p = 0.0078) (Figure 5E). The
reduction in striatopallidal GABA releasewas not due to impaired
synthesis and depletion of GABA, as LY341495 reversed the
effect of MSO readily. Additionally, the effects of LY341495 on
striatopallidal eIPSC amplitude were amplified in the presence
of MSO (control = 2.3 ± 0.9-fold, MSO = 4.8 ± 1.8-fold; p =
0.0433), consistent with the elevated level of glutamate in
ex vivo GPe tissue.
Chronic Dopamine Depletion Alters Astrocytic Gating of
Striatopallidal Signaling
As we have shown that Ca2+ signaling is altered in GPe astro-
cytes following chronic 6-OHDA lesion, it raises the question
of whether other key astrocytic functions, such as glutamate ho-
meostasis, are altered in PD and whether altered astrocytic
gating is responsible for increased striatopallidal GABA trans-
mission in PD. To test the hypothesis that glutamate levels are
altered in an in vivo setting, microdialysis was performed. As ex-
pected, dopamine levels in the GPe were greatly reduced in
chronic 6-OHDA-lesioned animals. The extracellular glutamate2438 Cell Reports 17, 2431–2444, November 22, 2016content in the GPe was also decreased. In contrast, glutamine
levels in the GPe were not altered (Figure S6).
If the decreased glutamate content in the GPe in vivo is a
consequence of altered astrocytic function, we should be able
to detect similar alterations in ex vivo brain slices. To investigate
potential alterations in glutamate content ex vivo, patch-clamp
recordings were performed to measure Ca2+-mediated striato-
pallidal GABA release and its regulation by group II mGluRs.
Following chronic 6-OHDA lesion, striatopallidal GABA release
(as measured with eIPSC amplitude) was enhanced across a
wide range of stimulation intensities (e.g., 500 mA: naive =
265.7 ± 126.6 pA, 6-OHDA = 653.7 ± 171.2 pA; p = 0.0410) (Fig-
ures 6A and 6B). Additionally, the increased striatopallidal GABA
release was further indicated by decreases in both CV and
paired-pulse ratio (Figure S5). The increased striatopallidal
GABA release was attributable to reduced group II mGluR activ-
ity, as LY341495 had a diminished effect on striatopallidal eIPSC
amplitude following chronic 6-OHDA lesion (e.g., 500 mA:
6-OHDA = 653.7 ± 171.2 pA, 6-OHDALY341495 = 702.3 ±
505.5 pA; p = 0.6430) compared to that in naive mice (e.g.,
500 mA: naive = 265.7 ± 126.6 pA, naiveLY341495 = 782.1 ±
324.2 pA; p = 0.0037). Importantly, LY341495 normalized the
difference between naive and chronic 6-OHDA lesion condition
in striatopallidal eIPSC amplitude (e.g., 500 mA: p = 0.4968)
(Figures 6A and 6B). Furthermore, the difference in release prob-
ability was eliminated by LY341495, as measured with the
CV and the paired-pulse ratio (Figure S5). A reduced effect
with LY341495 was also observed on Sr2+-mediated striatopal-
lidal GABA release (Figure S5). The diminished effect with
LY341495 was not due to a decreased mGluR3 expression,
as demonstrated by the fluorescence-activated cell sorting
(FACS)-qPCR analysis (Figure S4). Accordingly, LY379268
(a group II mGluR agonist) produced comparable effects on
striatopallidal GABA release in both naive and 6-OHDA-lesioned
mice (Figure S5).
To confirm that altered group II mGluR activity and striato-
pallidal GABA release indeed arises from chronic dopamine
depletion rather than nonspecific effects of 6-OHDA, a Cre-lox
strategy was used to abolish dopamine synthesis in nigral neu-
rons in homozygous mice carrying the floxed tyrosine hydroxy-
lase (Th) allele. Infection with Cre-AAV in the substantia nigra
generated a conditional tyrosine hydroxylase knockout (Th-
cKO), as evidenced by the loss of tyrosine hydroxylase at
both nigral and striatal levels (Figures 6D and 6E). Similar to
chronic 6-OHDA-lesioned mice, Th-cKO mice had a diminished
LY341495 effect on striatopallidal GABA release compared
to wild-type controls infected with a Cre-AAV (p = 0.0229)
or floxed-Th mice infected with a GFP-AAV (p = 0.0496) (wild-
typeCre-AAV = 2.1 ± 0.3-fold, Thfl/fl,GFP-AAV = 2.3 ± 0.2-fold,
Th-cKO = 1.3 ± 0.1-fold). This observation is similar to the differ-
ence between naive and chronic 6-OHDA-lesioned mice
(naiveLY341495 = 2.3 ± 0.9-fold, 6-OHDALY341495 = 1.4 ± 0.3-
fold; p = 0.0265) (Figure 6C). No difference between the two
chronic dopamine depletion paradigms was observed (p =
0.9394) (Figure 6C). The magnitude of increase in striatopallidal
GABA release by LY341495 was statistically indistinguishable
between naive and wild-type infection control (p = 0.6254).
These data argue that a disruption of group II mGluR-mediated
Figure 6. Increased dStr-GPe GABA
Release following Chronic Dopamine
Depletion Was due to a Decrease in
mGluR-Mediated Suppression
(A) Representative dStr-GPe eIPSCs evoked with
different stimulus intensities in various experi-
mental conditions. Top: note the difference be-
tween naive mice (black) and chronic 6-OHDA-
lesioned mice (red). Bottom: this difference was
normalized by bath application of LY341495
(200 nM), a group II mGluR antagonist.
(B) Data summary showing the stimulus-response
function of the dStr-GPe synapse with and without
group II mGluR antagonism from naive mice
(left) and chronic 6-OHDA-lesioned mice (right).
LY341495 greatly increased the dStr-GPe eIPSC
amplitude in naive mice (20 mA, p = 0.5287; 50 mA,
p = 0.0158; 100 mA, p = 0.0186; 200 mA, p = 0.0173;
500 mA, p = 0.0037), but not in 6-OHDA-lesioned
mice (20 mA, p = 0.2348; 50 mA, p = 0.0929; 100 mA,
p = 0.5345; 200 mA, p = 0.3882; 500 mA, p =
0.6430). Means ± SEMs are presented.
(C) Top: representative eIPSCs showing a dimin-
ished effect of LY341495 on dStr-GPe GABA
release in chronic 6-OHDA-lesioned mice. Middle:
conditional tyrosine hydroxylase knockout (Th-
cKO) mice were achieved with Cre delivery via an
adeno-associated virus (Cre-AAV) in the sub-
stantia nigra pars compacta (SNc) of a homozy-
gous floxed-Th (Thfl/fl) mouse. LY341495 had an
attenuated effect on dStr-GPe eIPSCs in this
chronic dopamine depletion model. Bottom left:
LY341495 displayed marked effect on dStr-GPe
eIPSCs in wild-type mice with SNc Cre-AAV
infection. Bottom right: boxplots summarize
the effect of LY341495 on dStr-GPe eIPSCs in
different experimental conditions (naive, n = 10
cells, p = 0.0020; 6-OHDA, n = 11 cells, p = 0.0049;
infection control, n = 13 cells, p = 0.0002; Th-cKO,
n = 9 cells, p = 0.0742). The effect of LY341495
was lower in chronic dopamine-depleted mice (naive versus 6-OHDA, p = 0.0265; infection control versus Th-cKO, p = 0.0112). No statistical significance
between chronic 6-OHDA and Th-cKO was found (p = 0.9394). Similarly, no statistical significance between naive and infection control was found (p = 0.4566).
(D) Top: photomicrograph of a coronal brain section from a Thfl/fl mouse showing an overview of tyrosine hydroxylase immunoreactivity in the dStr and neigh-
boring areas. Unilateral loss of tyrosine hydroxylase immunoreactivity in the dStr was observed in two mice with SNc Cre-AAV infection. Bottom: immunohis-
tochemical analysis of the SNc from the same animal in the top panel is shown. Ctx, cortex; Sp, septum.
(E) Immunohistochemical analysis similar to that shown in (D) was performed on a wild-type mouse with Cre-AAV infection in the SNc as an infection control
(infection ctrl).
Whiskers of the boxplots represent 10–90th percentiles.regulation of striatopallidal GABA release was a consequence of
chronic dopamine depletion rather than nonspecific toxic effects
of 6-OHDA or viral infection.
The impact of intracellular Ca2+ on the expression and activ-
ity of transporters on the astrocytic membrane has been widely
studied (Bazargani and Attwell, 2016). As we observed altered
Ca2+ signaling in GPe astrocytes following chronic 6-OHDA
lesion (Figures 1F and 1G), it is possible that decreased
ambient glutamate levels were a consequence of increased
astrocytic glutamate uptake. To this end, astrocytic glutamate
transporter activity was measured with glutamate uncaging
and whole-cell current-clamp recordings from SR101-labeled
GPe astrocytes. The astrocytic identity was further confirmed
by the ohmic current-voltage relationship (Figure 7A). Both
whole-cell conductance (naive = 24.6 ± 12.8 nS, n = 25;6-OHDA = 36.7 ± 16.6 nS, n = 15; p = 0.5388) and resting
membrane potential (naive = –71.6 ± 3.9 mV, n = 35;
6-OHDA = –69.6 ± 2.5 mV, n = 30; p = 0.0987) of GPe astro-
cytes were unaltered following chronic 6-OHDA lesion (data
not shown). Glutamate uncaging elicited depolarizing re-
sponses in GPe astrocytes (Figure 7B). These responses
were blocked with DL-TBOA (100 mM), a glutamate transporter
blocker (Figure S7). As ionotropic glutamate receptors and
neuronal activity were blocked in these experiments (see the
Supplemental Experimental Procedures), the release of neuro-
active substances from local neurons and terminals upon gluta-
mate uncaging was minimized. To our surprise, astrocytic
glutamate transporter activity was decreased following chronic
6-OHDA lesion (naive = 2.7 ± 0.4 mV, 6-OHDA = 2.2 ± 0.2 mV;
p = 0.0017) (Figure 7B).Cell Reports 17, 2431–2444, November 22, 2016 2439
Figure 7. Astrocytic Regulation of dStr-GPe
Release Was Disrupted following Chronic
6-OHDA Lesion
(A) Left: a composite micrograph of a GPe astro-
cyte (arrow). SR101 epifluorescence and differ-
ential interference contrast signals are shown.
Right: representative recording shows currents in
astrocytes elicited with a voltage ramp (from –150
to +50 mV) in naive (black) and 6-OHDA-lesioned
(red) mice.
(B) Left: representative voltage records of gluta-
mate transporter activity elicited with glutamate
uncaging in astrocytes from naive (black) and
6-OHDA-lesioned (red) mice. Right: boxplots
summarize the amplitude of glutamate transporter
potential of astrocytes in naive (black) and
6-OHDA-lesioned (red) mice (naive, n = 13 cells;
6-OHDA, n = 15 cells; p = 0.0017).
(C) Top left: representative eIPSCs showing a
lack of effect of optogenetic astrocyte activation
in chronic 6-OHDA-lesioned mice. Top middle:
average time course illustrates that optogenetic
astrocyte activation did not alter dStr-GPe eIPSC
amplitude. This was followed by LY341495 appli-
cation to demonstrate that group II mGluRs at the
dStr-GPe synapse were not near saturation in the
6-OHDA mice. Top right: boxplots summarize
the effect of optogenetic astrocyte activation on
dStr-GPe eIPSCs in naive and chronic 6-OHDA-
lesioned mice (naive, n = 8 cells, p = 0.0078;
6-OHDA, n = 8 cells, p = 0.4609). A difference
between the two conditions was observed (p = 0.0312). Bottom left: representative eIPSCs show the restoration of LY341495-induced enhancement on dStr-GPe
GABA release in the presence of MSO in the chronic 6-OHDA-lesioned mice. Bottom middle: boxplots summarize the effect of LY341495 on dStr-GPe eIPSC
amplitude following pretreatment with MSO (MSO: naive, n = 8 cells, p = 0.0078; 6-OHDA, n = 12 cells, p = 0.0024; LY341495 in MSO: naive, n = 10 cells,
p = 0.0020; 6-OHDA, n = 8 cells, p = 0.0078). A comparable effect of LY341495 on dStr-GPe eIPSC amplitude was found in naive and 6-OHDA-lesioned mice in
the presence of MSO (p = 0.8968). Bottom right: boxplots summarize the effect of LY341495 on dStr-GPe eIPSC CV following pretreatment with MSO (MSO:
naive, n = 8 cells, p = 0.0078; 6-OHDA, n = 12 cells, p = 0.0342; LY341495 in MSO: naive, n = 10 cells, p = 0.0020; 6-OHDA, n = 8 cells, p = 0.0078). A comparable
effect of LY341495 on dStr-GPe eIPSC CV was found in naive and 6-OHDA-lesioned mice in the presence of MSO (p = 0.8868).
Whiskers of the boxplots represent 10–90th percentiles. Means ± SEMs are presented for the time course plots.We hypothesized that the diminished ambient glutamate
levels in the GPe tissue following chronic dopamine depletion
arose from an impaired astrocytic glutamate release. As opto-
genetic activation of GPe astrocytes reliably induced gluta-
mate release, similar experiments were repeated in chronic
6-OHDA-lesioned mice. In contrast with observations in
naive mice, optogenetic activation of GPe astrocytes did not
induce changes in striatopallidal eIPSCs in 6-OHDA-lesioned
mice (astrocyte activation = 0.9 ± 0.3-fold, p = 0.4609) (Fig-
ure 7C). If GPe astrocytes have a diminished intracellular
content of glutamate, then blocking its conversion to gluta-
mine should restore glutamate release in chronic 6-OHDA-
lesioned mice. Consistent with this hypothesis, MSO inhibited
striatopallidal GABA release in 6-OHDA-lesioned mice as
measured by eIPSC amplitude (MSO = 0.4 ± 0.2-fold,
p = 0.0024) and CV (MSO = 1.4 ± 0.6-fold, p = 0.0342) (Fig-
ure 7C). LY341495 produced comparable effects in naive
and 6-OHDA conditions following the preincubation of MSO,
as measured with eIPSC amplitude (naive = 4.8 ± 1.8-fold,
6-OHDA = 3.5 ± 1.0-fold; p = 0.8968) and CV (naive = 0.4 ±
0.1-fold, 6-OHDA = 0.4 ± 0.1-fold; p = 0.8868) (Figure 7C).
These data indicate that reduced astrocytic glutamate content
contributes to the low ambient glutamate level and elevated2440 Cell Reports 17, 2431–2444, November 22, 2016striatopallidal GABA release in the chronic 6-OHDA-lesioned
mice.
DISCUSSION
Despite the importance of astrocytes in the maintenance of
proper neuronal function, only a handful of studies address the
roles of astrocytes in basal ganglia function in normal brain
states and dysfunction in PD. The classic circuit model predicts
an increased output of dStr indirect pathway projection neurons
in the absence of dopamine (Albin et al., 1989; DeLong, 1990). In
this study, we provided direct evidence for the increased striato-
pallidal release following the chronic loss of dopamine, and we
illuminated the contributions from GPe astrocytes.
Astrocytes Are Integral Parts of the Striatopallidal
System
While interactions between astrocytes and excitatory synapses
have been examined extensively, our findings argue that GPe as-
trocytes play an integral role at the GABAergic striatopallidal
synapse, which should be considered a tripartite synapse. In
addition to the supporting roles of GPe astrocytes (via clearance
and re-uptake of substrates) at the striatopallidal synapse
(Galvan et al., 2010), our data suggest that GPe astrocytes are
active partners in shaping the strength of the striatopallidal in-
puts. Specifically, by controlling extracellular glutamate levels
via the release and uptake process, GPe astrocytes suppress
striatopallidal release via presynaptic group II mGluRs.
We found that astrocytic control of glutamate homeostasis
in the GPe is responsive to chronic 6-OHDA lesion. The lower
ambient glutamate levels in the GPe tissue milieu following
chronic loss of dopamine led to a disinhibition of striatopallidal
input as a result of decreased group II mGluR activation. Impor-
tantly, boosting astrocytic glutamate content restored tonic
mGluR activity in the chronic 6-OHDA-lesioned mice. Our find-
ings are consistent with the literature that astrocytes are involved
in the maintenance of ambient glutamate, and this process is
altered in disease conditions (Cavelier et al., 2005; Featherstone
and Shippy, 2008; Halassa et al., 2007; Kalivas, 2009; Maragakis
and Rothstein, 2006; Sofroniew and Vinters, 2010).
Glutamate Content Is Highly Compartmentalized
Unlike gliotransmission reported in the majority of the studies
(Araque et al., 2014), ambient glutamate levels in ex vivo GPe
tissue were observed in the absence of external stimuli or
pharmacological manipulations. Tonic activation of presynaptic
mGluRs has been observed previously (Forsythe and Clements,
1990; Losonczy et al., 2003; McBain et al., 1994). Tonic activa-
tion of postsynaptic NMDA receptors in the hippocampus (Le
Meur et al., 2007), thalamus (Crabtree et al., 2013), and cere-
bellum has also been observed (Huang and Bordey, 2004).
These results demonstrate the presence of ambient glutamate
maintained in ex vivo tissue. Our current study extends the
idea that ambient glutamate is present in ex vivo GPe tissue.
It is conceivable that glutamate concentration is highly
cell compartment specific. While ambient glutamate in the
GPe can establish a steady-state desensitization of glutamate
receptors, especially AMPA receptors (Dingledine et al., 1999),
glutamate concentrations likely vary widely across cellular sub-
compartments, leaving AMPA receptors in the GPe functionally
intact. As group II mGluRs at the striatopallidal synapse are toni-
cally active, local glutamate levels at the striatopallidal synapses
can be in the submicromolar range based on the affinity of these
receptors to glutamate (Schoepp et al., 1999). In contrast, group
III mGluRs that are present at striatopallidal synapses and
exhibit micromolar affinity for glutamate are not tonically active
(Macinnes and Duty, 2008; Matsui and Kita, 2003; Valenti et al.,
2003).
The Origin of Ambient Glutamate in the GPe
To address the origin of ambient glutamate levels observed in
the ex vivo GPe tissue, we first excluded the contribution from
the principal glutamatergic input to the GPe (i.e., the STN) by
showing that (1) silencing the STN input did not alter ambient
glutamate levels and (2) direct stimulation of the STN-GPe input
similarly did not modulate striatopallidal GABA release. Using
optogenetic and pharmacological manipulations, we show that
GPe astrocytes have the capacity to elevate extracellular gluta-
mate content in ex vivo GPe tissue. These data argue that astro-
cytic release of glutamate can contribute to ambient glutamate
levels in the GPe tissue. However, whether GPe astrocytes arethe sole source of glutamate that is maintained in the GPe tissue
ex vivo requires further investigation. Importantly, we found
that elevation of astrocytic glutamate content restores gluta-
mate-mediated control of striatopallidal GABA release following
chronic 6-OHDA lesion. We argue that disruption of intracellular
glutamate homeostasis within GPe astrocytes contributes to al-
terations in tissue-level glutamate content and, subsequently, to
alterations in circuit-level dysfunction in PD. Our study extends
the literature on impaired astrocytic functions as a common
feature of neurodegenerative diseases (Halassa et al., 2007;
Lobsiger and Cleveland, 2007; Maragakis and Rothstein, 2006;
Sofroniew and Vinters, 2010).
Neuronal Influence on Glutamate Homeostasis in GPe
Astrocytes
The high levels of ambient glutamate in the GPe are not because
of poor uptake efficiency as a result of a low astrocyte density.
Instead, we found that the astrocyte-to-neuron ratio in the GPe
is roughly two-to-one, an order of magnitude higher than that
in the dStr. In contrast, we speculate that, as the maintenance
of the relatively high levels of glutamate in the GPe can be ener-
getically expensive, the high density of astrocytes within the GPe
should lessen the energetic burden on individual astrocytes.
Additionally, astrocyte number appears to correlate with the
high activity levels of GPe neurons both ex vivo and in vivo (He-
geman et al., 2016; Jaeger and Kita, 2011) and, thus, their high
metabolic demand (Harris et al., 2012). This idea is further sup-
ported by the high astrocyte-to-neuron ratio established by Pur-
kinje neurons and Bergmann glial cells in the cerebellum (Lafarga
et al., 1993). On the contrary, the astrocyte-neuron ratio in the
rodent cortex, which is metabolically less active, is one to three
(Nedergaard et al., 2003).
Biological Importance of Astrocytic Gating of
Striatopallidal Input
GPe astrocytes gate striatopallidal input via control of ambient
glutamate. This modulatory control increases the dynamic range
of the striatopallidal input and filters out unwanted, weak sig-
nals. This process could be important for encoding functional
segregation of movements within the GPe (Hegeman et al.,
2016; Jin et al., 2014; Shi et al., 2004; Turner and Anderson,
2005). The pathophysiology of PD can be explained by the
changes in the activity levels and synchrony in the GPe (Berg-
man et al., 1998; Chan et al., 2011; Hegeman et al., 2016; Her-
na´ndez et al., 2015; Kita and Kita, 2011). In a normal state,
individual GPe neurons respond specifically to the movement
in one direction of a single joint on the contralateral side. On
the contrary, individual GPe neurons in PD respond to move-
ments of multiple joints and body parts (Filion et al., 1988). As
dopamine is considered to be pivotal in isolating information
related to movements of specific body parts (Bergman et al.,
1998), it is intriguing to speculate that the crosstalk of informa-
tion related to different body parts in the absence of dopamine
in part arises from the disinhibition of striatopallidal GABA trans-
mission as a consequence of altered glutamate homeostasis.
Accordingly, restoring glutamate homeostasis in the GPe should
suppress striatopallidal GABA transmission and ameliorate
motor symptoms of PD.Cell Reports 17, 2431–2444, November 22, 2016 2441
EXPERIMENTAL PROCEDURES
All experiments detailed are in accord with the Northwestern University Animal
Care and Use Committee, the University of Michigan Unit for Laboratory Ani-
mal Medicine, and are in compliance with the NIH Guide for the Care and Use
of Laboratory Animals. All mice were on a C57BL/6 background. Unilateral
lesion of the nigrostriatal systemwas produced by 6-hydroxydopamine HCl in-
jection into the medial forebrain bundle of adult mice (postnatal days 28–35).
To genetically abolish nigral dopamine release, CMV-GFP-Cre AAV injections
were targeted to the substantia nigra pars compacta of homozygous floxed-Th
mice. For detection of glutamate in ex vivo slices, GFAP-iGluSnFr AAV was
injected into wild-type mice. For astrocyte-specific optogenetic activation, a
GfapCre mouse line was crossed with R26LSL-hChR2(H134R)-eYFP mouse line to
obtain astrocyte-specific expression of ChR2. Alternatively, EF1a-CreOn-
hChR2(H134R)-eYFP AAV was injected into the GPe of GfapCre mice. For
STN-specific optogenetic activation, hSyn-hChR2(H134R)-eYFP AAV was in-
jected into the STN of wild-type mice. To abolish STN glutamate release, a
tetanus toxin light chain (CMV-TeTLC-2A-eGFP)-expressing AAVwas injected
into the STN of wild-typemice; alternatively, CMV-eGFP-Cre AAVwas injected
into the STN of homozygous floxed-VGluT2 mice.
Mice at postnatal days 55–75were used for ex vivo experiments. SR101was
used to label astrocytes. To study the dStr inputs to the GPe, striatopallidal
axons were stimulated within the dStr using an electrical stimulus. To activate
ChR2 in astrocytes, a 1- to 2-s period of sustained blue light or pulsed blue light
(50ms each at 10 Hz) was used. For GCaMP3 and iGluSnFR imaging, standard
brain slices were prepared. Signals were acquired with a 60 3 1.0 numerical
aperture (NA) water-immersion objective, spinning-disk unit, and an elec-
tron-multiplying charge-coupled device (CCD). Standard procedures were
used for immunohistochemistry. Immunoreactivity was examined on a laser-
scanning confocal microscope with a 60 3 1.35 NA oil-immersion objective.
DataanalysesweredonewithClampFit10,MiniAnalysis, IgorPro6,MATLAB8,
Fiji, andPython3.Data in themain text arepresented asmedian values±median
absolute deviations as ameasure of central tendency and statistical dispersion,
respectively. Boxplots were used for graphic representation. Mann-Whitney
U test, Wilcoxon signed-rank test, and Fisher’s exact test were used.
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